Results of a prospective randomized trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) alone vs. ABVD plus radiation therapy for early stage non bulky Hodgkin's disease.

被引：0
|
作者：
Straus, DJ [1 ]
Yahalom, J [1 ]
Zelenetz, AD [1 ]
Qin, J [1 ]
Myers, J [1 ]
Moskowitz, CH [1 ]
Noy, A [1 ]
Bertino, JR [1 ]
Portlock, CS [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3201
引用
收藏
页码：769A / 769A
页数：1
相关论文
共 50 条
  • [31] A prospective trial of radiation alone vs combination chemotherapy alone for early-stage Hodgkin's disease: Implications of 25-year follow-up to current combined modality therapy.
    Longo, Dan L.
    Glatstein, Eli
    Duffey, Patricia L.
    Young, Robert C.
    Fiem, Shelby
    Jaffe, Elaine S.
    Camphausen, Kevin
    Wilson, Wyndham
    DeVita, Vincent T.
    BLOOD, 2006, 108 (11) : 33A - 33A
  • [32] Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial (vol 385, pg 1418, 2015)
    Behringer, K.
    Goergen, H.
    Hitz, F.
    LANCET, 2015, 385 (9976): : 1396 - 1396
  • [33] Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs 40 Gy extended field radiotherapy alone
    Duhmke, E
    Diehl, V
    Loeffler, M
    Mueller, RP
    Ruehl, U
    Willich, N
    Georgii, A
    Roth, S
    Matthaei, D
    Sehlen, S
    Brosteanu, O
    Hasenclever, D
    Wilkowski, R
    Becker, K
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 36 (02): : 305 - 310
  • [34] Cost evaluation of rituximab plus MCP vs. MCP alone in advanced stage indolent non-Hodgkin's-lymphoma based on a randomized controlled multicenter trial.
    Hieke, K
    Pasold, R
    Neser, S
    Niederwieser, D
    Neubauer, A
    Doelken, G
    Naumann, R
    Fietz, T
    Freund, M
    Rohrberg, R
    Hoeffken, K
    Franke, A
    Ittel, TH
    Kettner, E
    Haak, U
    Mey, U
    Klinkenstein, C
    Assmann, M
    von Gruenhagen, U
    Dachselt, K
    Schwenke, H
    Bleyl, D
    Wolf, H
    Hahnfels, S
    Hoffmann, FA
    Lakner, V
    Richter, P
    Haehling, D
    Hoffmann, FA
    Lakner, V
    Richter, P
    Haehling, D
    Wolf, HH
    Eschenburg, H
    Grobe, N
    Clemens, MR
    Herold, M
    BLOOD, 2004, 104 (11) : 28A - 29A
  • [35] Treatment of CSIA to IIIB non-bulky Hodgkin's disease (NB-HD) with 3 cycles of chemotherapy (CT) (ABVD vs EBVM) followed by high dose irradiation (RT).: Results of the GOELAMS H90-NM multicenter randomized trial.
    Desablens, B
    Jais, JP
    Lacotte-Thierry, L
    Foussard, C
    Escoffre-Barbe, M
    Moreau, P
    Ghandour, C
    Guilemin, F
    Casassus, P
    Maisonneuve, H
    Lemevel, A
    Traullé, C
    Colonna, P
    Andrieu, JM
    BLOOD, 1999, 94 (10) : 386A - 386A
  • [36] Risk-adapted therapy for clinical stage I-II Hodgkin's disease: 7-year results of radiotherapy alone for low-risk disease, and ABVD and radiotherapy for high-risk disease
    MacKenzie, RG
    Franssen, E
    Wong, R
    Sawka, C
    Berinstein, N
    Cowan, DH
    Senn, J
    Poldre, P
    CLINICAL ONCOLOGY, 2000, 12 (05) : 278 - 288
  • [37] Inter-clinician variability in treatment definition for involved-field radiotherapy of advanced Hodgkin's disease; results from the UK Stanford V vs. ABVD clinical trial quality assurance programme
    Diez, P
    Hoskin, PJ
    RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S423 - S423
  • [38] Prognostic factor tailored treatment of early stage Hodgkin's disease. Results from a prospective randomized phase III clinical trial in 762 patients (H7 study).
    Hagenbeek, A
    Carde, P
    Noordijk, E
    Thomas, J
    Tirelli, U
    Monconduit, M
    Eghbali, H
    Mandard, AM
    HenryAmar, M
    BLOOD, 1997, 90 (10) : 2603 - 2603
  • [39] Response-Guided ABVD Chemotherapy plus Involved-Field Radiation Therapy for Intermediate-Stage Hodgkin Lymphoma in the Pre-Positron Emission Tomography Era: A Gruppo Italiano Studio Linfomi (GISL) Prospective Trial
    Iannitto, Emilio
    Minardi, Viviana
    Gobbi, Paolo G.
    Calvaruso, Giuseppina
    Tripodo, Claudio
    Marclieselli, Luigi
    Luminari, Stefano
    Merli, Francesco
    Baldini, Luca
    Stelitano, Caterina
    Callea, Vincenzo
    Petrini, Mario
    Angrilli, Francesco
    Quarta, Giovanni
    Vallisa, Daniele
    Molica, Stefano
    Liardo, Eliana
    Polimeno, Giuseppe
    Brugiatelli, Maura
    Federico, Massimo
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (02): : 138 - 144
  • [40] Early Versus Late Intensification for Patients With High-Risk Hodgkin Lymphoma-3 Cycles of Intensive Chemotherapy Plus Low-Dose Lymph Node Radiation Therapy Versus 4 Cycles of Combined Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Myeloablative Chemotherapy With Autologous Stem Cell Transplantation Five-Year Results of a Randomized Trial on Behalf of the GOELAMS Group
    Arakelyan, Nina
    Berthou, Christian
    Desablens, Bernard
    de Guibert, Sophie
    Delwail, Vincent
    Moles, Marie-Pierre
    Quittet, Philippe
    Jais, Jean-Philippe
    Colonna, Pierre
    Andrieu, Jean-Marie
    CANCER, 2008, 113 (12) : 3323 - 3330
12345